What Causes Low GLP-1 | Genetic & Biomarker Factors

Last reviewed: May 25, 2026

Last updated: May 25, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Low GLP-1 levels stem from multiple interrelated factors: genetic variants affecting GLP-1 receptor expression, age-related decline in hormone production, insulin resistance, dietary composition, and gut dysbiosis. Research shows that GLP-1R genetic polymorphisms (such as rs6923761) may influence baseline glucagon-like peptide-1 secretion and receptor sensitivity.

For patients considering GLP-1 therapy—whether branded or compounded formulations—understanding why levels may be low can support more informed treatment conversations. PlexusDx focuses on precision-wellness insights: identifying genetic predispositions in peptide pathways allows providers to tailor dosing, formulation choice, and monitoring strategies to individual biochemistry.

Genetic Variants and GLP-1 Receptor Sensitivity

GLP-1 production and action depend partly on genetic inheritance. The GLP1R rs6923761 variant, among others, influences how efficiently your cells respond to GLP-1 signaling. Individuals carrying certain alleles may experience lower baseline GLP-1 levels or reduced receptor responsiveness, affecting natural appetite regulation and glucose metabolism.

Twin and family studies suggest 30-50% of GLP-1 pathway variation is heritable. This genetic foundation doesn't determine disease but provides context for why some people naturally produce or respond to GLP-1 differently. PlexusDx's Precision Peptide Genetic Test examines key variants in GLP1R and related pathways to reveal these predispositions.

Lifestyle and Metabolic Drivers of Low GLP-1

Beyond genetics, environmental and lifestyle factors directly suppress GLP-1 secretion. Chronic high-glycemic diets, sedentary behavior, sleep deprivation, and chronic stress all reduce L-cell GLP-1 production in the intestine. Insulin resistance—whether from obesity, poor diet, or metabolic syndrome—further dampens GLP-1 signaling effectiveness.

Factor	Impact on GLP-1 Levels
High-glycemic diet (refined carbs, ultra-processed foods)	Reduces L-cell GLP-1 secretion; promotes postprandial glucose spikes
Sedentary lifestyle and low physical activity	Decreases insulin sensitivity and blunts GLP-1 response to meals
Sleep deprivation (< 6 hours nightly)	Suppresses incretin hormone production; increases insulin resistance
Chronic psychological stress	Elevates cortisol, impairing L-cell function and GLP-1 release
Gut dysbiosis and reduced microbial diversity	Limits short-chain fatty acid production; reduces GLP-1 stimulus

Age-Related Decline and Metabolic Aging

GLP-1 secretion naturally declines with age, even in metabolically healthy individuals. Studies show that GLP-1 response to oral glucose decreases by 20-30% between ages 30 and 70. This age-related reduction in incretin effect contributes to postprandial hyperglycemia and reduced satiety signaling in older adults.

Concurrent changes in body composition, mitochondrial function, and gut barrier integrity amplify low GLP-1 impact. Aging also increases chronic inflammation, which impairs L-cell function. Understanding this trajectory helps providers contextualize why some individuals benefit from GLP-1 interventions earlier in metabolic decline.

Clinical Evaluation and Provider-Guided Next Steps

Diagnosing 'low GLP-1' clinically is uncommon because fasting GLP-1 levels are poorly standardized and not typically measured in routine care. However, clinical signs—such as impaired glucose tolerance, poor satiety, rapid weight regain, or metabolic syndrome—may suggest reduced GLP-1 function. Providers evaluate GLP-1 status indirectly through fasting glucose, HbA1c, lipid panels, and metabolic history.

PlexusDx's approach integrates genetic predisposition data (via Precision Peptide Genetic Test) with your clinical presentation to support provider decision-making. This biomarker-plus-genetics framework helps determine whether compounded GLP-1 therapy may align with your individual metabolic profile and whether doses, formulation (injection vs. oral), or monitoring intervals need adjustment.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test examines variants in GLP1R, GIPR, FTO, and MC4R—key genes regulating GLP-1 pathway function and metabolic response. The test may help provide context for why an individual experiences naturally lower GLP-1 effects or reduced appetite-suppression signaling. These predispositions should be interpreted with a qualified healthcare provider as part of a comprehensive metabolic assessment, not as diagnostic tools.

Genetic predispositions revealed by the Precision Peptide Genetic Test do not predict exact medication response or guarantee specific outcomes. Instead, they highlight individual variation in peptide-pathway biology—such as GLP1R sensitivity or FTO-related metabolic tendency. This information can support a more informed conversation between you and your provider about whether compounded GLP-1 therapy may be appropriate and what dose or formulation to consider.

Understanding your genetic and biomarker context empowers you to ask informed questions during provider consultations: Are my baseline GLP-1 levels measured or estimated? Do my genetic predispositions suggest higher or lower starting doses? Should I choose compounded injection or oral formulation based on my absorption profile? PlexusDx compounded semaglutide and tirzepatide offer flexible dosing that can be adjusted as you and your provider monitor response.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.